Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on August 10, 2017. The filing serves to announce the Company's financial results for the second quarter ended June 30, 2017. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1), which is not part of the provided text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of the Q2 2017 results.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information furnished under Item 2.02 and Exhibit 99.1:
- Is not deemed "filed" for purposes of Section 18 of the Exchange Act.
- Is not incorporated by reference into other filings unless specifically stated.
- Does not constitute an admission that the information is required under Regulation FD.
- Does not obligate the Company to update the information in the future.
No specific guidance, outlook, or risk factors are detailed in the text of the 8-K itself.
Investor Verification Checklist
- Verify the correct registrant name is Imprimis Pharmaceuticals, Inc., as the request metadata incorrectly listed "Harrow, Inc."
- Locate and review Exhibit 99.1 (the press release dated August 10, 2017) to obtain actual financial figures for the quarter ended June 30, 2017.
- Confirm that the financial results are not incorporated by reference into other SEC filings unless explicitly stated.